Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Modus Therapeutics Holding ABOSTO:MODTX -2.76%17 3-Year EBITDA Growth Rate is 13.10% as of Jun. 2026, which is 32% below its 10-year median of 19.30. GuruFocus rates OSTO:MODTX with a GF Score™ of 17/100. The stock has 1 warning sign investors should review. Among 1,127 Biotechnology companies, Modus Therapeutics Holding AB ranks worse than 51.91% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 13.10% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 2.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Modus Therapeutics Holding AB was 36.20% per year. The lowest was -35.30% per year. And the median was 19.30% per year.
Modus Therapeutics Holding AB (OSTO:MODTX) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Modus Therapeutics Holding AB 3-Year EBITDA Growth Rate Related Terms
OSTO:MODTX vs VRTX, REGN, MRNA: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Modus Therapeutics Holding AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Modus Therapeutics Holding AB 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Modus Therapeutics Holding AB's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Modus Therapeutics Holding AB's 3-Year EBITDA Growth Rate falls into.
Modus Therapeutics Holding AB 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 13.10% mean?
Modus Therapeutics Holding AB (OSTO:MODTX) has a 3-Year EBITDA Growth Rate of 13.10% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Modus Therapeutics Holding AB and its competitors. This is 32% below median its historical median of 19.30. According to the industry distribution chart, Modus Therapeutics Holding AB ranks #585 out of 1127 companies in the Biotechnology industry, placing it in the top 51.9%.
Is Modus Therapeutics Holding AB's 3-Year EBITDA Growth Rate too high?
Modus Therapeutics Holding AB's current 3-Year EBITDA Growth Rate of 13.10% is 32% below median its 10-year median of 19.30. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.60. Modus Therapeutics Holding AB's value of 13.10% is 10.3% below this industry median. Based on the distribution chart, Modus Therapeutics Holding AB ranks #585 out of 1127 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Modus Therapeutics Holding AB has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Modus Therapeutics Holding AB's 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Modus Therapeutics Holding AB ranks #585 out of 1127 companies for 3-Year EBITDA Growth Rate. This places Modus Therapeutics Holding AB in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.60. Modus Therapeutics Holding AB's value of 13.10% is 10.3% below this benchmark. While the company's 10-year median is 19.30 vs. the industry median of 14.60, Modus Therapeutics Holding AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.60, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Modus Therapeutics Holding AB's current 3-Year EBITDA Growth Rate of 13.10% is 10.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Modus Therapeutics Holding AB and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Modus Therapeutics Holding AB's current 3-Year EBITDA Growth Rate is 13.10%, which is 32% below median its own 10-year median of 19.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Modus Therapeutics Holding AB stock overvalued right now?
Modus Therapeutics Holding AB (OSTO:MODTX) has a current 3-Year EBITDA Growth Rate of 13.10%. The current 3-Year EBITDA Growth Rate is 13.10%, which is 32% below median its 10-year median of 19.30 and 10.3% below the Biotechnology industry median of 14.60. Modus Therapeutics Holding AB's overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Modus Therapeutics Holding AB (OSTO:MODTX), the current 3-Year EBITDA Growth Rate is 13.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Modus Therapeutics Holding AB is a Swedish biotechnology company developing its patented polysaccharide, sevuparin, as a potential treatment for unmet medical needs. Its research focuses on conditions involving severe systemic inflammation, including sepsis and septic shock, severe malaria, and other related disorders, as well as anemia associated with chronic inflammatory conditions such as kidney disease.
17GF Score
Get the complete analysis for OSTO:MODTX
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:MODTX has been successfully added to your 
